Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 5/20 | 0.82 |
| ▸ | CAMK2D | Q13557 | 6/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | BCR | P11274 | 1/20 | 0.62 |
| ▸ | PRKCA | P17252 | 1/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.62 |
| ▸ | CDK4 | P11802 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4732841 | 0.91 | PLK1 (1.00) | PLK1CAMK2DABL1BCRPRKCA | |
| SCHEMBL4905928 | 0.88 | PLK1 (0.72) | PLK1CAMK2DABL1BCRPRKCA | |
| SCHEMBL4786087 | 0.88 | PLK1 (0.78) | PLK1CAMK2DABL1PRKCAPRKCD | |
| SCHEMBL14651462 | 0.88 | PLK1 (0.84) | PLK1CAMK2DABL1BCRPRKCA | |
| SCHEMBL4737520 | 0.84 | PLK1 (0.73) | PLK1CAMK2DABL1BCRPRKCA | |
| SCHEMBL4907230 | 0.84 | PLK1 (1.00) | PLK1CAMK2DABL1BCRCDK4 | |
| SCHEMBL2946515 | 0.84 | PLK1 (0.77) | PLK1CAMK2DABL1BCRPRKCA | |
| SCHEMBL27643199 | 0.83 | PIK3CA (0.74) | PLK1CAMK2DCDK4MAPTCDK2 | |
| SCHEMBL4736259 | 0.83 | PLK1 (1.00) | PLK1CAMK2DABL1BCRPRKCA | |
| SCHEMBL4735987 | 0.83 | PIK3CA (0.68) | PLK1CDK4CDK2PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | claimed |
| WO-2008065155-A1 | CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | claimed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| JP-2007500179-A | — | — | 2007-01-11 | — | — | JP | claimed |
| CN-1860104-A | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LTD (GB) | 2006-11-08 | — | — | CN | claimed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | claimed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| CN-1860104-A | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LTD (GB) | 2006-11-08 | — | — | CN | disclosed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | PLK1 1603/4885CAMK2D 1264/4885ABL1 684/4885 |
| US-20080153822-A1 | Methods of treating pain | OPRL1, ACHE, OPRK1 | PLK1 3544/4885CAMK2D 1498/4885ABL1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.